Dry Eye Syndrome (DES)

Error message

Notice: Undefined variable: script in googleanalytics_page_alter() (line 284 of /home/svitzory/domains/svit-zory.com.ua/public_html/sites/all/modules/google_analytics/googleanalytics.module).

Dry Eye Syndrome (DES), or xerosis of cornea and conjunctiva, is a complex disease spread worldwide. Dry Eye Syndrome is one of the main problems of modern ophthalmic pathology. According to the data of the native researchers, about 12% of ophthalmologic patients aged up to 40 years and more than 67% of patients older than 50 years suffer from this disorder. The «dry eye syndrome» concept is determined as a group of signs of corneal and conjunctival epithelium damage owing to reduction in the quality and/or quantity of lachrymal fluid. Lachrymal fluid forms on the ocular surfaces a tear film, which fulfills a number of very important functions, including trophic, protective and optic. Therefore, compositional or production disorder of tear film can result in rather serious damages of the anterior eye segment.

Dry Eye Syndrome starts with a characteristic symptom – the feeling of a foreign body in the conjunctival cavity coupled with abundant lacrimation later followed by the feeling of dryness. Typical are complaints of burning and “sandpaper” in the eyes, especially under the influence of wind, smoke, conditioned air and other similar irritants, when using fan heaters. Additionally, dry eye syndrome has subjective signs: photophobia, deterioration of visual performance towards evening, fluctuations in visual acuity within one working day.

Treatment of dry eye syndrome is determined according to the disease severity. In case of light degree of the disease, the initial “symptomatic” treatment is administration of lacrimal substitutes protecting corneal epithelium against desiccation and having temporary facilitatory effect (unction and wetting of ocular surfaces).

If treatment of dry eye syndrome with lacrimal substitutes was noneffective, ointments and/or gels are used. Anti-inflammatory therapy with Restasis (cyclosporine А 0,05% ophthalmic emulsion) is also recommended.

Dry Eye Syndrome (DES), Treatment of Dry Eye Syndrome Restasis ™ manufactured by Allergan, USA, is a fundamentally new approach in dry eye syndrome treatment, since the drug eliminates the cause of the disease – inflammation of ocular surfaces (inactivates the inflammation mediators - interleukines). As a result, natural production of tear revives, quality and quantity of tear normalize.

Treatment of dry eye syndrome with this drug has been widely used in USA for more than seven years (approved by FDA), and from September 2011 Restasis ™ is available in Ukraine. At the ophthalmologic clinic SVIT ZORU You can get qualified advice of an optometrist in the presence of the disease first symptoms. A doctor will examine the condition of the anterior eye segment and prescribe adequate treatment of dry eye syndrome depending on the severity of illness. You will be also able to obtain complete information of this drug and the possibility for you particularly to use it.

Indications for use:

Ophthalmic emulsion Restasis™ is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammatory associated with dry keratoconjunctivitis.

Contra indications:

Hypersensitivity to cyclosporine А and additive agents, which are found in the drug; acute infectious eye diseases; pediatric use.

Adverse reactions:

When using Restasis™ the feeling of burning of the affected eye was observed most often (in 17% of cases). In 1-5% of cases the following side effects were reported: conjunctival hyperemia, eye discharge, pain, feeling of a foreign body in the eye, pruritus, burning, visual impairment (blurred vision mostly), allergic reactions.

Peculiarities of use:

In patients with herpesvirus keratitis in past medical history the drug use is not investigated.

Emulsion contained in one bottle for individual application should be used immediately after opening the bottle – the drug is instilled in both eyes. The drug which remained in the dropper bottle should be utilized immediately after application. Prevent contact of the bottle nozzle with eyes and any surface to avoid contamination of the bottle contents.

You should not use Restasis™ if you are wearing contact lenses. Patients with low tear production are not usually recommended to wear contact lenses. If you do wear contact lenses, take them out before using the emulsion. You may put them back in 15 minutes after using Restasis™.

Bottles are kept in their original packaging before use.

We offer you to join us at the reception